Yaşar Erdoğan, Öztürk Kara Deniz, Yıldırım Nilgün
Aksaray University Aksaray Training and Research Hospital, Ophthalmology Clinic, Aksaray, Turkey.
Aksaray University Aksaray Training and Research Hospital, Dermatology Clinic, Aksaray, Turkey.
Turk J Ophthalmol. 2018 Jun;48(3):146-149. doi: 10.4274/tjo.78614. Epub 2018 Jun 28.
A 21-year-old male patient with no history of systemic disease or drug use presented to our clinic with redness and pain in the right eye. Best corrected visual acuity was 20/20 in both eyes. Inflamed pinguecula was observed on slit-lamp examination and the patient was prescribed ophthalmic nepafenac eye drops. After instilling the drops that day and the next day, the patient presented again due to pruritus and rash. Upon consultation with the dermatology department, the patient was diagnosed with drug-induced allergic urticaria and the nepafenac drops were discontinued. Although urticaria has been reported as a side effect after systemic non-steroidal anti-inflammatory drug (NSAID) use, such a reaction has not been reported with an ophthalmic NSAID and ours is the first reported case of urticaria following ophthalmic nepafenac use. This unique case highlights the fact that ophthalmologists must also keep urticaria in mind as a potential side effect when prescribing this drug.
一名21岁男性患者，无全身性疾病史或用药史，因右眼发红、疼痛前来我院就诊。双眼最佳矫正视力均为20/20。裂隙灯检查发现睑裂斑炎，遂给患者开具了奈帕芬酸眼药水。在当天及次日滴眼药水后，患者因瘙痒和皮疹再次前来就诊。经皮肤科会诊，患者被诊断为药物性过敏性荨麻疹，停用了奈帕芬酸眼药水。虽然全身性使用非甾体抗炎药（NSAID）后荨麻疹已被报道为一种副作用，但眼科用NSAID尚未有此类反应的报道，我们的病例是首次报道使用眼科用奈帕芬酸后出现荨麻疹。这一独特病例凸显了眼科医生在开具此药时也必须将荨麻疹视为潜在副作用这一事实。
